Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL585463 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL4274094 | 0.86 | CHRM2 (0.40) | CHRM2CHRM1CHRM3HSD17B10CYP1A2 | |
| SCHEMBL3243618 | 0.86 | CHRM2 (0.40) | CHRM2CHRM1CHRM3HSD17B10CYP1A2 | |
| SCHEMBL18660256 | 0.82 | CHRM2 (0.49) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL15058137 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL21073336 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL15058138 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL21073334 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL15058136 | 0.79 | CHRM2 (0.46) | CHRM2CHRM1CHRM3HSD17B10PREP | |
| SCHEMBL3248189 | 0.77 | NR1H2 (0.34) | CHRM2CHRM1CHRM3CYP1A2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2102217-B1 | 4- (2-OXO-OXAZOLIDIN-3YL)-PHENOXYMETHYLE DERIVATIVEAS AS ANTIBACTERIALS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-8039466-B2 | 5-hydroxymethyl-oxazolidin-2-one antibacterials | ACTELION PHARMACEUTICAL LTD. (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | ACTELION PHARMACEUTICALS, LTD. (CH) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069376-A1 | 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS | OGFOD1, ODC1, OXGR1 | CHRM2 1192/4885CHRM1 365/4885CHRM3 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.